Navigation Links
Scientists unravel resistance to breast cancer treatment
Date:10/31/2012

Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.

Tamoxifen used alongside traditional chemotherapy and radiotherapy blocks the female hormone oestrogen that, in certain breast cancers, is required by the tumour to grow; it has been shown to improve cancer survival rates by up to one third.

However, about one third of patients with the appropriate type of breast cancer known as oestrogen receptor positive breast cancer do not respond to tamoxifen or develop resistance to the drug. Oestrogen receptor positive breast cancer is the most common form of the disease accounting for 70% of cases.

Now, a team from the University of Manchester's Paterson Institute for Cancer Research has identified a molecular flag or biomarker that will help doctors predict which patients will respond best to complementary (adjuvant) hormone therapy with tamoxifen.

"The identification of molecular flags to classify subgroups of breast cancer and so determine the best treatment for each patient is of increasing importance in cancer therapy," said study lead Professor Gran Landberg.

"Tamoxifen has been shown to be highly effective in some breast cancer patients when used alongside traditional cancer therapies but, in a third of cases, the result has not been what we would hope. If we can predict which patients will respond to tamoxifen, and those who won't, then this is clearly advantageous as it means the correct treatment is provided instantly which will improve disease outcomes."

The research, funded by the charity Breakthrough Breast Cancer and published in the journal PLoS One, looked at the connective tissue surrounding the tumour, which is known to send signals that help the cancer to grow. The team, part of the Manchester Cancer Research Centre, found that fibroblast cells the cells that make up connective tissue in ou
'/>"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester
Source:Eurekalert

Page: 1 2

Related biology news :

1. Stanford scientists build the first all-carbon solar cell
2. Gladstone, Stanford scientists block toxic protein that plays key role in Lou Gehrigs disease
3. Scientists deepen genetic understanding of MS
4. Whitehead scientists identify major flaw in standard approach to global gene expression analysis
5. USDA scientists collaborate with global researchers to advance the mapping of the barley genome
6. Scientists uncover mechanism by which plants inherit epigenetic modifications
7. CT scan and 3-D print help scientists reconstruct an ancient mollusk
8. Scientists conclude high fructose corn syrup should not be blamed for obesity
9. Maintaining Earths sustainability: Scientists, engineers, educators take coordinated approach
10. UMN scientists get federal grant for biotechnology development to purify fracking water
11. Scientists reveal how natural antibiotic kills tuberculosis bacterium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... its altitude, ozone can be either friend or foe. ... scientists will now have a better understanding of ozone, its origin ... polluting our atmosphere. Ozone is a colourless, toxic gas named ... In the stratosphere, acting as friend, ...
... wildflower, grows from the Mississippi River to Arizona and ... plant can be seen covering large areas of plains, ... Working to create a new drought-resistant and water-saving ... and Soil Science have introduced ,Raider Amethyst, a new ...
... a page from Nature herself, a team of researchers ... from the atmosphere and place it in the Earth,s ... the new technology does not make the oceans more ... process is a manipulation of the natural weathering of ...
Cached Biology News:Ozone intrusions -- humankind's fault? 2Scientists enhance Mother Nature's carbon handling mechanism 2
(Date:5/1/2015)... 2015 Investor-Edge has initiated ... (NASDAQ: GENE ), Agilent Technologies Inc. (NYSE: ... TMO ), Sequenom Inc. (NASDAQ: SQNM ... Free research report on Genetic Technologies can be ... 30, 2015, the NASDAQ Composite ended at 4,941.42, ...
(Date:4/30/2015)... South Carolina (PRWEB) May 01, 2015 ... system services, is extremely proud to announce that for ... been named as a winner of a Queen’s Award ... success for the design and manufacture of a unique ... is the revolutionary alternative to traditional steam flow measurement. ...
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... chemicals, today announced that it has commenced an underwritten public ... to grant the underwriters a 30-day option to purchase ... of common stock offered in the public offering. The ... be no assurance as to whether or when the ...
(Date:4/30/2015)... Budapest, Hungary (PRWEB) April 30, 2015 ... electronic lab notebook with integrated protocols and specimen ... chemistry software solutions and consulting services for life ... the development of Labguru’s newest feature: chemical structure ... deep domain features for biologists, bio-chemists, and more, ...
Breaking Biology Technology:Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... York, May 26, 2012 Sanofi ... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today ... trial of SAR236553/REGN727 (Study 1003, NTC01266876) in patients ... subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase ...
... decades, neurologists have known that a diet high in fat ... resist drug therapy. But how the diet worked, and why, ... York Times Magazine called it "Epilepsy,s Big, Fat Miracle." ... School have proposed an answer, linking resistance to seizures to ...
... growth of crystals, do nanoparticles act as "artificial atoms" ... structures? This is the contention of a major but ... researchers at the U.S. Department of Energy (DOE),s Lawrence ... and point the way to energy devices of the ...
Cached Biology Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 2Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 3Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 4Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 5Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 6Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 7Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 8Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 9Reverse engineering epilepsy's 'miracle' diet 2Reverse engineering epilepsy's 'miracle' diet 3Nanoparticles seen as artificial atoms 2Nanoparticles seen as artificial atoms 3
TXNL2 Antibody...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Biology Products: